Cargando…
CIS-platin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy has had limited success in clinical trials. One barrier to implementation of efficacious immune therapies is a lack of knowledge of the effect of chemotherapy on the monocyte-derived component of the...
Autores principales: | Hopkins, Daniel, Sanchez, Hector, PhD, Brent Berwin, MD, Ivy Wilkinson-Ryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450249/ https://www.ncbi.nlm.nih.gov/pubmed/34530192 http://dx.doi.org/10.1016/j.tranon.2021.101217 |
Ejemplares similares
-
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
por: Kumar, Smriti, et al.
Publicado: (2011) -
A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases
por: Wilkinson-Ryan, Ivy, et al.
Publicado: (2018) -
Dendrimers Bind Antioxidant Polyphenols and cisPlatin Drug
por: Abderrezak, Amine, et al.
Publicado: (2012) -
Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture.
por: Kohno, N., et al.
Publicado: (1988) -
On the Mechanism of Action of the Antitumor Drug cis-Platin
(cis-DDP) and its Second Generation Derivatives
por: Aletras, Vasilis, et al.
Publicado: (1995)